| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Factor Xa (FXa). Dechloro Rivaroxaban is a highly potent and selective, orally active, direct inhibitor of the active site of FXa, the key serine protease in the final common pathway of the coagulation cascade. It has a Ki of 0.4 nM against human free FXa.
|
|---|---|
| ln Vitro |
Dechloro Rivaroxaban is a highly selective, direct inhibitor of Factor Xa. It inhibits free FXa with a Ki of 0.4 nM. It inhibits prothrombinase activity with an IC50 of 2.1 nM and fibrin-associated FXa activity with an IC50 of 92 nM. These values indicate it is a potent inhibitor of both soluble and clot-bound FXa. Its selectivity for FXa over other proteases in the coagulation cascade is expected to be high, based on the profile of its parent drug, Rivaroxaban.
|
| ln Vivo |
In vivo, Dechloro Rivaroxaban is an orally bioactive, selective inhibitor of Factor Xa. As an analog of Rivaroxaban, it is predicted to have excellent oral bioavailability and potent antithrombotic activity in animal models of venous and arterial thrombosis. By inhibiting FXa, it reduces thrombin generation, fibrin clot formation, and platelet activation. The lack of the chlorine atom may subtly alter its PK or selectivity profile.
|
| Enzyme Assay |
The potency of Dechloro Rivaroxaban against FXa is determined in cell-free enzyme assays. Human Factor Xa is incubated with a chromogenic substrate (e.g., S-2765, a FXa-specific peptide-pNA conjugate) in a buffer containing Tris-HCl, NaCl, and CaCl2. Dechloro Rivaroxaban is added at concentrations ranging from 0.01-1000 nM. The reaction is monitored by the increase in absorbance at 405 nm. The Ki (0.4 nM) is calculated from the rate of pNA release. Selectivity is assessed by testing the compound against a panel of other coagulation proteases (thrombin, FIXa, FVIIa, FXIa, FXIIa, and activated protein C).
|
| Cell Assay |
Cellular assays are not typical for direct FXa inhibitors, as FXa functions as a soluble protease in the plasma. However, the inhibition of prothrombinase activity can be assessed in a cellular context. The prothrombinase complex is assembled on the surface of activated platelets or endothelial cells. Dechloro Rivaroxaban is added to the reaction, and the generation of thrombin is measured using a chromogenic thrombin substrate. The ability to inhibit fibrin-associated FXa is also tested in a system where FXa is bound to pre-formed fibrin clots.
|
| Animal Protocol |
Dechloro Rivaroxaban is orally active. In vivo efficacy studies would be performed in standard animal models of thrombosis. For example, in a rat model of venous thrombosis, the compound would be administered orally at doses of 1-10 mg/kg. The endpoint is the reduction in thrombus weight. In a model of arterial thrombosis (e.g., FeCl3-induced carotid artery injury), the endpoint is the time to occlusion. The pharmacodynamic effect would be measured as the prolongation of the prothrombin time (PT) in plasma samples.
|
| ADME/Pharmacokinetics |
Dechloro Rivaroxaban has a molecular formula of C19H19N3O5S and a molecular weight of 401.44 g/mol. Based on its structural similarity to Rivaroxaban, it is expected to have high oral bioavailability (>80% in humans). It is metabolized primarily by CYP3A4 and is a substrate of the efflux transporters P-gp and BCRP. The half-life is expected to be 5-9 hours, supporting once-daily dosing. Detailed PK data are not provided for this specific analog.
|
| Toxicity/Toxicokinetics |
No detailed toxicological data are available for Dechloro Rivaroxaban. However, as an analog of a clinically approved drug, it is likely to have a similar safety profile. The parent drug, Rivaroxaban, is generally well-tolerated. The major adverse event is bleeding (e.g., gastrointestinal bleeding, intracranial hemorrhage). Allergic reactions and hepatotoxicity are also known but rare. The dechloro analog may have a different selectivity profile. It is intended for research use only.
|
| References | |
| Additional Infomation |
Dechloro Rivaroxaban is primarily used as an analytical reference standard and a research tool. It is a known impurity of Rivaroxaban and is used in quality control. It is not an FDA-approved drug. Its utility lies in understanding the structure-activity relationship of the oxazolidinone class of FXa inhibitors. It is sold for research purposes only and should not be used in humans.
|
| Molecular Formula |
C19H19N3O5S
|
|---|---|
| Molecular Weight |
401.44
|
| Exact Mass |
401.104
|
| CAS # |
1415566-28-7
|
| PubChem CID |
66926287
|
| Appearance |
White to off-white solid powder
|
| Density |
1.400±0.06 g/cm3 (20 ºC 760 Torr)
|
| Boiling Point |
758.0±60.0 °C(Predicted)
|
| Melting Point |
216-218 °C
|
| LogP |
1.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
610
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=CS4
|
| InChi Key |
SJVCANNMDYDYLN-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C19H19N3O5S/c23-17-12-26-8-7-21(17)13-3-5-14(6-4-13)22-11-15(27-19(22)25)10-20-18(24)16-2-1-9-28-16/h1-6,9,15H,7-8,10-12H2,(H,20,24)/t15-/m0/s1
|
| Chemical Name |
N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4910 mL | 12.4552 mL | 24.9103 mL | |
| 5 mM | 0.4982 mL | 2.4910 mL | 4.9821 mL | |
| 10 mM | 0.2491 mL | 1.2455 mL | 2.4910 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
